EyePoint, Inc. Common Stock (EYPT)
LABORATORY ANALYTICAL INSTRUMENTS
- Headquarters
- United States
- Employees
- 214
- Market Cap
- $1.1B
About EyePoint, Inc. Common Stock
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
SentiSense also tracks daily options readings for EyePoint, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
EyePoint, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.